Best of ASCO® Montreal 2024: Myeloma – Dr. Richard LeBlanc
OR
Co-Chairs
Dr. Jamil Asselah
Dr. Kim Ma
Speakers
Dr. Richard LeBlanc
Studies/trials discussed:
- Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Analysis of minimal residual disease (MRD) IN PERSUS trial.
- Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ).
- Phase 3 randomized study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus isard in patients with newly diagnosed transplant ineligible multiple myeloma (NDMM TI).
- DREAMM-7 update: Subgroup analyses from a phase 3 trial of belantamab mafodotin (belamaf) + bortezomib and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM).
- Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin
- plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib
- and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM).
- Ciltacabtagene autoleucel vs standard of care in patients with functional high-risk multiple myeloma: CARTITUDE-4 subgroup analysis.
- Efficacy and safety of ciltacabtagene autoleucel ± lenalidomide maintenance in newly diagnosed multiple myeloma with suboptimal response to frontline autologous stem cell transplant: CARTITUDE-2 cohort D.
